Market/Novel Tech

GenSight Biologics has reported a natural history for LHON (with ND4 mutations) showing that a novel treatment could provide a convincing benefit. 

GenSight Biologics Inc., (EURONEXT: SIGHT), Paris, France, has announced the results from the final analysis of the REALITY natural history study, which reaffirms the poor… Read More »GenSight Biologics has reported a natural history for LHON (with ND4 mutations) showing that a novel treatment could provide a convincing benefit. 

A UK gene therapy company (MeiraGTx) has announced positive clinical data for the treatment of X-linked retinitis pigmentosa (XLRP)

MeiraGTx (Nasdaq: MGTX), has announced six-month data from an ongoing phase 1/2 clinical trial of AAV-RPGR for the treatment of patients with X-linked retinitis pigmentosa (XLRP).… Read More »A UK gene therapy company (MeiraGTx) has announced positive clinical data for the treatment of X-linked retinitis pigmentosa (XLRP)